ATNM Actinium Pharmaceuticals, Inc. Stock Quote

ATNM [AMEX]

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	1.55%	Shs Outstand	15.43M	Perf Week	1.81%
Market Cap	116.59M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	0.00%	Shs Float	13.38M	Perf Month	-26.82%
Income	-20.40M	PEG	-	EPS next Q	-0.37	Inst Own	26.70%	Short Float	7.93%	Perf Quarter	-29.63%
Sales	-	P/S	-	EPS this Y	34.20%	Inst Trans	20.73%	Short Ratio	2.01	Perf Half Y	-37.51%
Book/sh	2.94	P/B	2.87	EPS next Y	23.70%	ROA	-64.60%	Target Price	-	Perf Year	2.55%
Cash/sh	3.49	P/C	2.42	EPS next 5Y	-	ROE	-78.00%	52W Range	4.71 - 19.47	Perf YTD	8.08%
Dividend	-	P/FCF	-	EPS past 5Y	30.50%	ROI	-	52W High	-56.70%	Beta	1.08
Dividend %	-	Quick Ratio	10.50	Sales past 5Y	-	Gross Margin	-	52W Low	78.98%	ATR	0.55
Employees	25	Current Ratio	10.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.72	Volatility	4.81% 5.83%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	70.40%	Profit Margin	-	Rel Volume	0.83	Prev Close	8.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	527.65K	Price	8.43
Recom	1.80	SMA20	-9.07%	SMA50	-19.47%	SMA200	-13.80%	Volume	436,047	Change	1.57%

Nov-05-20

Initiated

Alliance Global Partners

Buy

$25

Dec-06-17

Initiated

B. Riley FBR, Inc.

Buy

$2.75

Oct-23-17

Resumed

ROTH Capital

Buy

Sep-14-17

Initiated

Maxim Group

Buy

Aug-25-16

Initiated

ROTH Capital

Buy

Feb-29-16

Initiated

H.C. Wainwright

Buy

Oct-15-15

Initiated

FBR Capital

Outperform

$12

Oct-01-14

Initiated

MLV & Co

Buy

$16

Jul-22-14

Initiated

Canaccord Genuity

Buy

$16

Jan-13-21 07:00AM	Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies PR Newswire
Dec-29-20 08:30AM	Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial PR Newswire -24.63%
Dec-23-20 05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Dec-17-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-09-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know Zacks
08:00AM	Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit PR Newswire
Dec-08-20 08:00AM	Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH PR Newswire
Dec-07-20 08:30AM	Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting PR Newswire
08:15AM	Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting PR Newswire
07:00AM	Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting PR Newswire
Dec-03-20 07:00AM	Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting PR Newswire
Dec-02-20 08:49PM	Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now? Insider Monkey
05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Dec-01-20 07:00AM	Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development PR Newswire -6.64%
Nov-23-20 07:00AM	Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity PR Newswire
Nov-20-20 05:45PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Nov-19-20 07:30AM	Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs PR Newswire
Nov-16-20 07:00AM	Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium PR Newswire +5.25%
Nov-13-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
Nov-11-20 08:00AM	Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials PR Newswire
Nov-04-20 12:21PM	100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML PR Newswire +10.25%
12:13PM	Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting PR Newswire
12:00PM	Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting PR Newswire
Oct-29-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Oct-28-20 07:00AM	Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook PR Newswire
Oct-22-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
Oct-21-20 08:04AM	The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga +7.58%
07:00AM	Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy PR Newswire
Oct-14-20 07:00AM	Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform PR Newswire
Oct-09-20 06:37AM	We Think Actinium Pharmaceuticals (NYSEMKT:ATNM) Can Afford To Drive Business Growth Simply Wall St.
Oct-08-20 05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Oct-06-20 07:00AM	Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial PR Newswire
Oct-02-20 05:45PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Sep-23-20 07:00AM	Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients PR Newswire -9.36%
Sep-14-20 07:00AM	Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin PR Newswire +8.33%
Sep-10-20 07:00AM	Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference PR Newswire
Aug-31-20 06:05PM	LD Micro: 360 Companies Set to Present this Week ACCESSWIRE
Aug-28-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Aug-26-20 08:48AM	Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season? Zacks
Aug-12-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-10-20 02:30PM	Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split PR Newswire -8.28%
12:00PM	Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy? Zacks
Aug-04-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Aug-03-20 11:54AM	Actinium (ATNM) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-28-20 05:50PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Jul-27-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks +10.92%
Jul-23-20 12:00PM	Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy? Zacks
Jul-21-20 08:57AM	Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options Zacks +16.30%
Jul-20-20 10:32AM	Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue? Zacks +12.43%
Jul-15-20 07:03AM	Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-09-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-08-20 09:05AM	The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio Zacks
Jun-19-20 05:15PM	Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering PR Newswire
Jun-17-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks -14.61%
Jun-16-20 11:30PM	Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering PR Newswire +9.47%
04:01PM	Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering PR Newswire
Jun-15-20 11:29PM	Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock? Zacks -9.67%
Jun-12-20 08:43AM	How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry Zacks +6.91%
Jun-09-20 08:47AM	Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7% Zacks +39.81%
Jun-04-20 09:45PM	Hedge Funds Cautiously Watching Actinium Pharmaceuticals Inc (ATNM) Insider Monkey +30.98%
09:42AM	Benzinga's Top Upgrades, Downgrades For June 4, 2020 Benzinga
Jun-03-20 09:53AM	3 Strong Buy Healthcare Stocks Under $5 With Big Upside Potential TipRanks
Apr-24-20 05:15PM	Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-21-20 11:35PM	Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering PR Newswire
04:01PM	Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering PR Newswire
Apr-16-20 07:00AM	Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020 PR Newswire
Apr-12-20 09:02AM	Can Actinium Pharmaceuticals (NYSEMKT:ATNM) Afford To Invest In Growth? Simply Wall St.
Mar-06-20 10:56AM	Actinium Treats First Patient in AML Study on Actimab-A Combo Zacks
Mar-05-20 07:30AM	Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia PR Newswire +16.43%
Feb-26-20 07:33AM	Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients PR Newswire
Feb-25-20 09:33AM	Actinium (ATNM) to Report Q4 Earnings: What's in the Cards? Zacks -6.08%
Feb-21-20 07:30AM	Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT) PR Newswire
Feb-13-20 08:03AM	Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation PR Newswire
Feb-05-20 05:50PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
08:03AM	Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire
Jan-30-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 12:00PM	Actinium (ATNM) Upgraded to Strong Buy: Here's Why Zacks +9.60%
07:15AM	One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price Simply Wall St.
07:03AM	Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma PR Newswire
Jan-07-20 07:03AM	Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase PR Newswire
Jan-03-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Jan-02-20 09:29AM	Tilray (TLRY) in Focus: Stock Moves 9% Higher Zacks +9.14%
Dec-22-19 05:08PM	Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM) Insider Monkey
Dec-09-19 06:10AM	Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting PR Newswire -9.56%
06:00AM	Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy PR Newswire
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-01-19 09:30AM	The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-20-19 09:00AM	What Makes Actinium (ATNM) a New Buy Stock Zacks
Nov-07-19 04:05PM	Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference PR Newswire
Nov-06-19 09:15AM	Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019 PR Newswire
09:00AM	Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019 PR Newswire
Oct-28-19 08:20AM	Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment PR Newswire -29.36%
Oct-15-19 10:48AM	What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM)? Simply Wall St.
Sep-30-19 08:00AM	Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa PR Newswire
Sep-23-19 08:00AM	Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts PR Newswire
Sep-16-19 08:00AM	Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment PR Newswire
Jul-23-19 08:00AM	Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B PR Newswire +14.27%
Jul-17-19 12:56PM	How Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Can Impact Your Portfolio Volatility Simply Wall St.
Jul-11-19 08:00AM	Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers PR Newswire
Jun-26-19 08:00AM	Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting PR Newswire

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience